Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Coverage Restrictions For Expensive Drugs: Did Aduhelm Let The Genie Out Of The Bottle?

Executive Summary

Payer discomfort with accelerated approvals exploded into the public arena with the Medicare national coverage determination on Aduhelm and similar drugs, and developers worry that the fallout will be far reaching.

You may also be interested in...



Medicare Restrictions On Aduhelm Do Not Signal Broad Concern With Accelerated Approvals – CMS

CMS chief medical officer Lee Fleisher addresses concerns that the Medicare national coverage determination for Alzheimer’s drugs sets a precedent for accelerated approvals. He and the FDA's Janet Woodcock also discuss prospects for closer collaboration on evidence needs pre-approval.

Medicare Alzheimer’s Decision Varies Evidence Mandate For Accelerated vs. Traditional Approvals

Final Medicare national coverage determination aims to set up a ‘nimble’ system to allow for broad and rapid patient access to drugs for Alzheimer’s disease following traditional approval while retaining a more restrictive approach for accelerated approvals.

CMS Input On Pivotal Trials Could Anticipate Medicare Coverage Issues – Brooks-LaSure

Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure responds to US Congressional concerns about the proposed Medicare coverage policy for Alzheimer’s drugs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel